3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
17
Rituximab
11
fludarabine
9
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Busulfan
7
fludarabine phosphate
6
Tacrolimus
6
Melphalan
6
Whole-Body Irradiation
5
Doxorubicin
5
Vincristine
4
Prednisone
4
Mesna
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
ibrutinib
3
Thiotepa
3
Sirolimus
3
Cyclosporine
3
Bortezomib
3
ponatinib
2
Vorinostat
2
Stem Cell Transplantation
2
Rifampin
2
Platelet Transfusion
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
CLR1404
×
Lymphoid
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled